卵巢癌患者血清HB-EGF水平及与临床病理参数和预后的关系  

Relationships between serum HB-EGF level and clinicopathological parameters,prognosis in patients with ovarian cancer

作　　者：徐雁飞[1] 聂敦利[1] 曾敏[1] XU Yan-Fei;NIE Dun-Li;ZENG Min(Department of Gynecology and Obstetrics,the First People's Hospital of Chengdu,Chengdu,Sichuan 610041,China)

机构地区：[1]成都市第一人民医院妇产科,四川成都610041

出　　处：《中国妇幼保健》2020年第10期1911-1914,共4页Maternal and Child Health Care of China

基　　金：四川省卫生厅科研基金项目(150235)。

摘　　要：目的分析卵巢癌患者血清肝素结合性表皮生长因子(HB-EGF)水平及与临床病理参数和预后的关系。方法选择2010年1月-2013年6月在成都市第一人民医院诊治的141例卵巢癌患者为卵巢癌组,另选择同期100例健康女性为对照组。采用酶联免疫吸附法(ELISA)检测两组血清HB-EGF水平,分析卵巢癌组血清HB-EGF水平与患者临床病理参数及预后的关系。结果卵巢癌组血清HB-EGF水平为(604.38±192.49)ng/ml,显著高于对照组[(393.74±115.66)ng/ml],差异有统计学意义(P<0.05)。不同淋巴结转移情况、FIGO分期、肿瘤大小的卵巢癌患者血清HB-EGF水平比较差异有统计学意义(P<0.05)。HB-EGF高表达组(>566.59 ng/ml)卵巢癌患者5年总生存率低于HB-EGF低表达组(≤566.59 ng/ml),差异有统计学意义(P<0.05)。多因素分析显示:FIGO分期、术后残留病灶大小和术前血清HB-EGF水平是影响卵巢癌患者预后的独立危险因素。结论HB-EGF在卵巢癌患者血清中高表达,与肿瘤进展有关,是导致卵巢癌不良预后的危险因素。Objective To analyze the relationships between serum heparin-binding epidermal growth factor(HB-EGF)level and clinicopathological parameters,prognosis in patients with ovarian cancer.Methods A total of 141 patients with ovarian cancer were selected from the First People's Hospital of Chengdu from January 2010 to June 2013 as ovarian cancer group,100 healthy women during the same period were selected as control group.ELISA was used to detect the levels of serum HB-EGF in the two groups.The relationships between serum HB-EGF level and clinicopathological parameters,prognosis in ovarian cancer group were analyzed.Results The level of serum HBEGF in ovarian cancer group was(604.38±192.49)ng/ml,which was statistically significantly higher than that in control group[(393.74±115.66)ng/ml](P<0.05).There was statistically significant difference in serum HB-EGF level among the patients with lymph node metastasis or not,different FIGO stages,and tumor sizes(P<0.05).Five-year survival rate in HB-EGF high expression ovarian cancer group(>566.59 ng/ml)was statistically significantly lower than that in HB-EGF low expression ovarian cancer group(≤566.59 ng/ml)(P<0.05).Multivariate analysis showed that FIGO staging,postoperative residual size,and preoperative serum HB-EGF level were independent risk factors for prognosis of ovarian cancer patients.Conclusion HB-EGF is highly expressed in serum of patients with ovarian cancer,it is related to tumor progression,HB-EGF is a risk factor for poor prognosis of ovarian cancer patients.

关 键 词：卵巢癌 肝素结合性表皮生长因子 病理参数 预后 

分 类 号：R737.31[医药卫生—肿瘤]